EUVIMEDEUVIMED entdecken
Open Access

Quantifying the Renal Impact of [ 177 Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry

Thomas Büttner, Christian Hoffmann, Markus Essler, Florian Gärtner, Barbara Kreppel, Jim Küppers, Manuel Ritter, Leander Fritzsche, Milka Marinova, Philipp Krausewitz

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.271077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Thomas Büttner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany; and thomas.buettner@ukbonn.de. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Registries, Lutetium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to clarify the renal safety of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC), addressing emerging reports of nephrotoxicity.

Methods

We retrospectively analyzed patients with mCRPC from the real-world LUMEN registry who received 3 or more cycles of [177Lu]Lu-PSMA-617. The endpoint was the change in estimated glomerular filtration rate (eGFR) over 24 mo, assessed using linear mixed-effects models.

Results

Analysis of 261 patients revealed a modest average decline in eGFR of -0.15 mL/min/1.73 m2 per month (95% CI, -0.25 to -0.05; P = 0.005), translating to -1.80 mL/min/1.73 m2 per year (95% CI, -3.03 to -0.57). The rate of loss accelerated by approximately -0.1 per year per additional gigabecquerel of administered activity (95% CI, -0.18 to -0.01; P = 0.028). Conclusion: [177Lu]Lu-PSMA-617 is associated with a slight long-term average decline in eGFR. Although this is unlikely to be clinically relevant for late-stage mCRPC, the cumulative dose effect warrants careful monitoring in earlier disease stages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesHeterocyclic Compounds, 1-RingRegistriesLutetiumKidneyProstatic Neoplasms, Castration-ResistantHeterocyclic CompoundsHumansMaleAgedRetrospective StudiesLongitudinal StudiesGlomerular Filtration RateMiddle AgedAged, 80 and overRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

177LuPSMAeGFRkidneymCRPC

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177PSMA-617RadioisotopesHeterocyclic CompoundsProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany; and thomas.buettner@ukbonn.de.
  • Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany; and.
  • Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

Zitieren

APA

Büttner, T., Hoffmann, C., Essler, M., Gärtner, F., Kreppel, B., Küppers, J., Ritter, M., Fritzsche, L., Marinova, M., & Krausewitz, P. (2026). Quantifying the Renal Impact of [ 177 Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271077

Vancouver

Büttner T, Hoffmann C, Essler M, Gärtner F, Kreppel B, Küppers J, et al. Quantifying the Renal Impact of [ 177 Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.271077

BibTeX
@article{Bttner2026,
  author = {Büttner, Thomas and Hoffmann, Christian and Essler, Markus and Gärtner, Florian and Kreppel, Barbara and Küppers, Jim and Ritter, Manuel and Fritzsche, Leander and Marinova, Milka and Krausewitz, Philipp},
  title = {Quantifying the Renal Impact of [ 177 Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.271077}
}
Kostenlos starten →